Open label single arm clinical study to evaluate the effectiveness of Pittaghna Kala Basti in the management of Chirotha Amlapitta.

Amlapitta is one of the commonest prevalent diseases in society, primarily influenced by factors such as poor dietary habits, lifestyle changes, poor maintenance of food timings and prolonged medication. It predominantly affects younger and middle-aged individuals, with a prevalence rate of 78.8% in the general population, notably 48.9% for acute cases and 29,9% for chronic cases’. In India, 3 in 869 individuals are suffering from the disease .77.2% among them are adult aged 19 to 26 years. Despite the abundance of available treatments in all medical systems, none can fully cure the condition, leading to recurrent symptoms and dependence on medications, often proceeds to chronic Amlapitta. This highlights the need for effective preventive measures. Hence, the disease is being chosen for the study.

Basti stands out as the premier treatment for Vata disorders, but its efficacy extends equally to Pitta, Kapha, and Rakta imbalances. Specifically addressing Pitta imbalances, Charaka recommends the administration of five to six Anuvasana Basti. Even though Basti exits the intestine quickly, the potency of the medications still spreads throughout the interneurons of the gut, exerting an impact on the enteric nervous system. Notably, he emphasizes the use of Pittaghna Basti formulations, which possess qualities such as Tikta. Madhura Rasa. Snigdha and Sheeta Basti treatment is given the higher prevalence of chronic cases, there’s a significant focus on addressing them. Specifically, for Chirotha Amla Pitta Asthapana and Anuvasana Bastis are recommended. Hence, Pittaghna Basti may be effective in alleviating the condition.